Senesco was previously granted orphan drug status for SNS01-T.
Senesco plans to evaluate SNS01-T in patients with relapsed or refractory disease who have failed at least two standard treatment regimens.
Senesco president and CEO Leslie Browne said their first IND submission is a significant milestone for Senesco.
"It is designed to regulate what we believe is an important growth control switch that induces programmed cell death, also known as apoptosis," Browne said.
"If this therapeutic approach is successful, we believe it has the potential to change the progression of the disease and significantly impact patients’ lives."